<DOC>
	<DOCNO>NCT01411228</DOCNO>
	<brief_summary>A protocol extend assessment safety efficacy taliglucerase alfa pediatric subject ( 2 &lt; 18 year old ) symptoms clinical manifestation Gaucher disease complete treatment Protocols PB-06-002 ( switchover study imiglucerase ) PB-06-005 ( na√Øve treatment taliglucerase alfa ) .</brief_summary>
	<brief_title>A Multicenter Extension Study Taliglucerase Alfa Pediatric Subjects With Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Successful completion Protocol PB06002 PB06005 The subject , parent ( ) legal guardian ( ) sign inform consent and/or assent Currently take another investigational drug condition . Presence neurological sign symptom characteristic Gaucher disease complex neuronopathic feature longstanding oculomotor gaze palsy . Presence medical , emotional , behavioral psychological condition judgment Investigator would interfere subject 's compliance requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gaucher disease</keyword>
	<keyword>pediatrics</keyword>
</DOC>